A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Clinical trial NCT03918278 · COMPLETED
Trial details
- NCT number
- NCT03918278
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-19
- Primary completion
- 2025-06-09
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.